Marie L. Jones - 17 Sep 2024 Form 4 Insider Report for Silk Road Medical Inc

Reporting relationship: VP, Finance and CAO
Issuer ticker: N/A
Reported as of: 17 Sep 2024
Net transaction value: -$1,886,149
SEC form: 4
Accepted by SEC: 18 Sep 2024, 20:35:13 UTC
Prior SEC filing: 05 Mar 2024
Next SEC filing: 07 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Marie Jones

Key filing fact

Marie L. Jones filed Form 4 for Silk Road Medical Inc on 18 Sep 2024.

Key facts

This page summarizes Marie L. Jones's Form 4 filing for Silk Road Medical Inc.
3 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 18 Sep 2024, 20:35.

Change

Previous filing in this sequence was filed on 05 Mar 2024.
Current net transaction value: -$1,886,149.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SILK transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -79,266
Change %: -100%
Price
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Footnotes: F1, F2, F3, F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SILK transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value: $1,532,829
Shares: -71,661
Change %: -100%
Price: $21.39
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 71,661
Exercise price: $6.11
Footnotes: F5

SILK transaction Derivative

Employee Stock Option (right to buy)

Disposed to Issuer

Transaction value: $353,320
Shares: -16,518
Change %: -100%
Price: $21.39
Shares after: 0
Date: 17 Sep 2024
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 16,518
Exercise price: $6.11
Footnotes: F6

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Marie L. Jones is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 6 footnotes

Footnote F1

Of the reported shares, 49,414 are represented by restricted stock units, or RSUs, each of which represents a contingent right to receive one share of Issuer common stock.

Footnote F2

Includes 2,000 shares and 372 shares acquired under the Issuer's 2019 Employee Stock Purchase Plan on May 20, 2024 and September 13, 2024, respectively.

Footnote F3

Pursuant to the Agreement and Plan of Merger dated June 17, 2024, between the Issuer, Boston Scientific Corporation and Seminole Merger Sub, Inc, (the "Merger Agreement"), each share of Issuer common stock was canceled and converted into the right to receive $27.50 per share in cash (the "Merger Consideration"), without interest and subject to applicable withholding taxes.

Footnote F4

Pursuant to the Merger Agreement, each RSU was canceled and converted into the right to receive an amount in cash, without interest, equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares underlying the RSUs, less applicable taxes and authorized deductions.

Footnote F5

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $1,532,828.79 which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.

Footnote F6

The shares subject to the option are fully vested and immediately exercisable. Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $353,320.02, which represents the difference between (i) the amount by which the Merger Consideration exceeded the exercise price of the option per share option and (ii) the aggregate number of shares remaining issuable upon exercise of the option, less applicable taxes and authorized deductions.